Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects-Reference-Cited by-同舟云学术

Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects

Published:2020-04-21 Issue:5 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wu Guolan¹²,Tang Wenling³,Lv Duo¹²,Wu Lihua¹²,Zhou Huili¹²,Yang Xi⁴,Zheng Yunliang¹²,Zhai You¹²,Shentu Jianzhong¹²

Affiliation:

1. Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

2. Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

3. College of Medicine, Zhejiang University, Hangzhou, China

4. Department of Pharmacy, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Abstract

The effects of multiple-dose administration of tenofovir disoproxil fumarate (TDF) on the pharmacokinetics of morinidazole (MOR) were compared in healthy subjects. MOR exposure was similar, with an area under the curve from 0 h to infinity (AUC 0-∞ ) treatment ratio for MOR+TDF/MOR of 1.01 (90% confidence interval, 0.97 to 1.06). No relevant differences were observed regarding plasma exposure of metabolites. Renal clearances of MOR and its metabolites were not affected by TDF.

Funder

National Natural Science Foundation of China

NSF | Foundation for Innovative Research Groups of the National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02067-19

Reference15 articles.

1. Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial

2. Lv A. October 2008. Usage of alpha-(morpholin-1-base) methyl-2-methyl-5-azathio-1-alcohol in preparation of anti-trichomoniasis and anti-ameba medicines. China patent ZL 200510134254.3.

3. Metabolism and Pharmacokinetics of Morinidazole in Humans: Identification of Diastereoisomeric Morpholine N+-Glucuronides Catalyzed by UDP Glucuronosyltransferase 1A9

4. Effects of Renal Impairment on the Pharmacokinetics of Morinidazole: Uptake Transporter-Mediated Renal Clearance of the Conjugated Metabolites

5. Renal Transporters in Drug Disposition, Drug‐Drug Interactions, and Nephrotoxicity

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing morinidazole for surgical site infection in class III wounds prevention: a multi-centre, randomized, single-blind, parallel-controlled study;Journal of Hospital Infection;2024-09

2. Pharmacokinetic Drug-Drug Interactions Involving Antiretroviral Agents: An Update;Current Drug Metabolism;2023-07